Salarius Pharmaceuticals, Inc. 8-K

What Happened Salarius Pharmaceuticals, Inc. (SLRX) filed an 8-K (Item 3.01) saying it received a Nasdaq notice on December 31, 2025 that its common stock is not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price was under the $1.00 minimum for the last 30 consecutive business days. Nasdaq determined the company is not eligible for the usual 180-day compliance period due to Nasdaq Rule 5810(c)(3)(A)(iv) and the company having effected a reverse stock split within the prior year while subject to a Mandatory Panel Monitor. Unless Salarius requests an appeal by January 7, 2026, Nasdaq will schedule the securities for delisting and suspend trading at the opening on January 9, 2026 and file Form 25‑NSE to remove the securities from Nasdaq registration. The company intends to request an appeal with a Nasdaq Hearings Panel on or before January 7, 2026; that appeal request will stay the suspension and Form 25‑NSE filing pending the panel’s decision. The filing notes there is no assurance the appeal will be successful.

Key Details

• Notice received: December 31, 2025; filing date of 8-K: January 2, 2026.
• Rule cited: Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price) and ineligibility under Rule 5810(c)(3)(A)(iv).
• Appeal deadline to prevent suspension: January 7, 2026; suspension scheduled at market open on January 9, 2026 if no appeal.
• Company action: Intends to appeal to a Nasdaq Hearings Panel; appeal request will stay suspension and Form 25‑NSE filing pending the hearing.

Why It Matters A Nasdaq delisting determination means the company’s shares could be removed from Nasdaq trading and registration unless the Hearings Panel grants relief — an outcome the company is actively contesting. For investors, delisting can affect where and how the stock trades, visibility, and liquidity; the company’s timely appeal will determine whether trading is suspended while the matter is decided. The filing contains no guarantee of a favorable outcome.